Dengue virus (DENV) causes dengue fever, the most prevalent arthropod-borne viral illness in humans (NIAID Category A pathogen). Globally, the four serotypes of DENV cause an estimated 100 million new cases of dengue fever and 250,000 cases of dengue hemorrhagic fever (DHF) per year. Currently, no specific therapy is available, and vaccines are still in early stages of development. Given that the most advanced tetravalent live attenuated DENV vaccine candidate showed a poor 30% overall efficacy rate in a recently published phase 2b clinical trial, there remains a pressing need for new approaches for safe, effective vaccines. In the first cycle of this R01 we developed a large panel of ~500 novel monoclonal antibodies (MAbs) against all four DENV serotypes and analyzed the structural, biophysical, and cellular mechanisms of Ab-mediated neutralization of several of them. These studies defined novel epitopes on DENV E proteins recognized by inhibitory antibodies (Abs), many of which are not solvent-accessible according to existing atomic models of the virus particle. Our studies revealed that the structure of DENV was more complex than anticipated and is likely a heterogeneous and structurally dynamic ensemble of different states, each of which may interact differentially with Ab. In this renewal application, we propose to define the spectrum of structural states sampled by the DENV virion, determine the structural basis of differential neutralization of individual DENV serotype by cross-reactive, fusion-loop specific Abs, and assess the role of anti-prM Abs in recognition and neutralization of DENV. This information will be translated into developing a novel inactivated vaccine strategy that traps DENV particles in structural states that preferentially elicit highly neutralizing Abs.

Public Health Relevance

The goal of this application is to define new states of DENV particle structure and determine how these interact with specific MAbs. This information will be translated into developing a novel DENV vaccine strategy that traps virions in states that preferentially elicit highly neutralizing Abs.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Virology - B Study Section (VIRB)
Program Officer
Cassetti, Cristina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Plevka, Pavel; Battisti, Anthony J; Sheng, Ju et al. (2014) Mechanism for maturation-related reorganization of flavivirus glycoproteins. J Struct Biol 185:27-31
Kaufmann, Barbel; Vogt, Matthew R; Goudsmit, Jaap et al. (2010) Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A 107:18950-5
Fuchs, Anja; Lin, Tsai-Yu; Beasley, David W et al. (2010) Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 8:186-95
Cherrier, Mickael V; Kaufmann, Barbel; Nybakken, Grant E et al. (2009) Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J 28:3269-76
Kaufmann, Barbel; Chipman, Paul R; Holdaway, Heather A et al. (2009) Capturing a flavivirus pre-fusion intermediate. PLoS Pathog 5:e1000672
Rodrigo, W W Shanaka I; Block, Olivia K T; Lane, Christopher et al. (2009) Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 394:175-82
Mehlhop, Erin; Nelson, Steevenson; Jost, Christiane A et al. (2009) Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe 6:381-91
Thompson, Bruce S; Moesker, Bastiaan; Smit, Jolanda M et al. (2009) A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog 5:e1000453
Rajamanonmani, Ravikumar; Nkenfou, Celine; Clancy, Paula et al. (2009) On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 90:799-809
Pierson, Theodore C; Fremont, Daved H; Kuhn, Richard J et al. (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-38

Showing the most recent 10 out of 11 publications